These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 11994042)

  • 1. Economic evaluation of gemcitabine alone and in combination with cisplatin in the treatment of nonsmall cell lung cancer.
    Lees M; Aristides M; Maniadakis N; McKendrick J; Botwood N; Stephenson D
    Pharmacoeconomics; 2002; 20(5):325-37. PubMed ID: 11994042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
    Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial).
    Reaume MN; Leighl NB; Mittmann N; Coyle D; Hirsh V; Seymour L; Tu D; Shepherd FA; Graham B; Gridelli C; Perrone F; Di Maio M; Bradbury PA; Evans WK
    Lung Cancer; 2013 Oct; 82(1):115-20. PubMed ID: 23962449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of gemcitabine in non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic Treatment Disease Site Group.
    Evans WK; Kocha W; Gagliardi A; Eady A; Newman TE
    Cancer Prev Control; 1999 Feb; 3(1):84-94. PubMed ID: 10474757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost-effectiveness of four cisplatin-containing chemotherapy regimens in the treatment of stages III B and IV non-small cell lung cancer: an Italian perspective.
    Palmer AJ; Brandt A
    Monaldi Arch Chest Dis; 1996 Aug; 51(4):279-88. PubMed ID: 8909011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-minimization analysis for Portugal of five doublet chemotherapy regimens from two phase III trials in the treatment of advanced non-small cell lung cancer.
    Pimentel FL; Bhalla S; Laranjeira L; Guerreiro M
    Lung Cancer; 2006 Jun; 52(3):365-71. PubMed ID: 16650499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic evaluation in a randomized phase III clinical trial comparing gemcitabine/cisplatin and etoposide/cisplatin in non-small cell lung cancer.
    Sacristán JA; Kennedy-Martin T; Rosell R; Cardenal F; Antón A; Lomas M; Alberola V; Massuti B; Carrato A; Minshall M
    Lung Cancer; 2000 May; 28(2):97-107. PubMed ID: 10717327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic value of gemcitabine compared to cisplatin and etoposide in non-small cell lung cancer.
    Copley-Merriman C; Corral J; King K; Whiteside R; Voi M; Dorr FA; McDonald RC
    Lung Cancer; 1996 Feb; 14(1):45-61. PubMed ID: 8696720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma.
    Danson S; Middleton MR; O'Byrne KJ; Clemons M; Ranson M; Hassan J; Anderson H; Burt PA; Fairve-Finn C; Stout R; Dowd I; Ashcroft L; Beresford C; Thatcher N
    Cancer; 2003 Aug; 98(3):542-53. PubMed ID: 12879472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paclitaxel: a pharmacoeconomic review of its use in non-small cell lung cancer.
    Plosker GL; Hurst M
    Pharmacoeconomics; 2001; 19(11):1111-34. PubMed ID: 11735678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic evaluation of gemcitabine single agent therapy compared with standard treatment in stage IIIB and IV non-small cell lung cancer.
    Tennvall GR; Fernberg JO
    Med Oncol; 1998 Jul; 15(2):129-36. PubMed ID: 9789222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer.
    Noble S; Goa KL
    Drugs; 1997 Sep; 54(3):447-72. PubMed ID: 9279506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective cost analysis of gemcitabine in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in Europe.
    Schiller J; Tilden D; Aristides M; Lees M; Kielhorn A; Maniadakis N; Bhalla S
    Lung Cancer; 2004 Jan; 43(1):101-12. PubMed ID: 14698544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
    Abdel-Rahman O; Elsayed Z; Elhalawani H
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale of a phase III study comparing a standard cisplatin regimen (mitomycin/ifosfamide/cisplatin) with cisplatin and gemcitabine in non-small cell lung cancer.
    Tonato M; Crinó L; Mosconi AM
    Semin Oncol; 1997 Jun; 24(3 Suppl 8):S8-31-S8-35. PubMed ID: 9207314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic evaluation of three two-drug chemotherapy regimens in advanced non-small-cell lung cancer.
    Neymark N; Lianes P; Smit EF; van Meerbeeck JP
    Pharmacoeconomics; 2005; 23(11):1155-66. PubMed ID: 16277550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decision framework for chemotherapeutic interventions for metastatic non-small-cell lung cancer.
    Berthelot JM; Will BP; Evans WK; Coyle D; Earle CC; Bordeleau L
    J Natl Cancer Inst; 2000 Aug; 92(16):1321-9. PubMed ID: 10944554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of vinorelbine alone or vinorelbine plus cisplatin for stage IV NSCLC.
    Evans WK
    Oncology (Williston Park); 1998 Mar; 12(3 Suppl 4):18-25; discussion 25-6. PubMed ID: 9556779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost-effectiveness of navelbine alone or in combination with cisplatin in comparison to other chemotherapy regimens and best supportive care in stage IV non-small cell lung cancer.
    Evans WK; Le Chevalier T
    Eur J Cancer; 1996 Dec; 32A(13):2249-55. PubMed ID: 9038606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The activity of gemcitabine plus cisplatin in randomized trials in untreated patients with advanced non-small cell lung cancer.
    Rosell R; Tonato M; Sandler A
    Semin Oncol; 1998 Aug; 25(4 Suppl 9):27-34. PubMed ID: 9728582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.